Please login to the form below

Not currently logged in
Email:
Password:

Catalent appoints two board members

Jack Stahl and Rolf Classon to advise drug development, delivery and supply company
catalent-rolf-classon

Catalent has named two experienced healthcare figures to its board of directors.

Jack Stahl, former CEO of cosmetics firms Revlon, and Rolf Classon, former chairman at Bayer Healthcare, will use to their experience to advise Catalent, a leading player in providing drug development, delivery and supply services to pharma companies.

Stahl headed Revlon from 2002 to 2006 following a stint as chief operating officer at the Coca-Cola Company. He also serves on the Boards of Coty, Delhaize Group, and the US board of advisers of CVC Capital.

Classon served as chairman at Bayer Healthcare from 2002 until 2004 as part of a long career at Bayer that began in 1991. His roles at the German company included a seven-year spell as president of Bayer Diagnostics.

“We welcome both Jack and Rolf to our Board,” said John Chiminski, President and CEO, Catalent. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector.”

20th August 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....

Infographics